Star Scientific, Inc. Refutes Story Published on

        Star Scientific, Inc. Refutes Story Published on

PR Newswire

GLEN ALLEN, Va., Jan. 28, 2013

GLEN ALLEN, Va., Jan. 28, 2013 /PRNewswire/ --Star Scientific, Inc. (NASDAQ:
STSI) commented today on a January 23, 2013, column appearing on That piece contains numerous false and misleading statements
regarding the Company's anatabine research and the initial results of the ASAP
Human Thyroid Health Study released by Star Scientific on January 7, 2013. 

(Logo: )

As reported in the Company's January 7, 2013, press release: "The preliminary
examination of the primary outcomes shows a clear and statistically
significant difference in the treated group as compared to the placebo group
by the end of the trial, with declines in anti-thyroglobulin antibody levels.
Anatabine subjects also tended toward a reduction in thyroid gland vascularity
on ultrasound relative to placebo."

The ASAP study, which examines the impact of anatabine dietary supplementation
on thyroid health, was conducted by Rock Creek Pharmaceuticals, the Company's
subsidiary. The study was not sponsored by the Johns Hopkins School of
Medicine, and the Company never reported otherwise. Indeed, when Star
Scientific first announced IRB approval of this study on February 9, 2012, it
noted that the study was being conducted by Rock Creek Pharmaceuticals at
sites in Texas, Illinois, and Florida. The Company also consistently
referenced that this study was being conducted by Rock Creek Pharmaceuticals
at multiple sites in subsequent press releases, including the January 7, 2013,
release. Any implication by the author of the article in that
Star Scientific stated otherwise is patently false.

The statement that there is no science backing that anatabine reduces
inflammation similarly is completely false. Since 2011, Rock Creek
Pharmaceuticals and researchers at the Roskamp Institute have completed and
reported on a number of studies designed to assess the ability of the
Company's anatabine compound to lower chronic inflammation in a variety of
pre-clinical (non-human) and clinical (human) settings. One study conducted by
the Roskamp Institute and reported in The Journal of European Pharmacology in
2011 showed that anatabine lowered levels of amyloid production both in the
test tube and when administered to mice vulnerable to accumulation of amyloid
which, at excessive levels damages brain tissue. A second manuscript written
by the same researchers and published online in The Journal of European
Pharmacology in 2012 and in manuscript form in January 2013 further
characterized the anti-inflammatory effects of anatabine in several types of
animal tissues, in human cells, and in human whole blood. The Roskamp
Institute also presented results of pre-clinical studies of anatabine in mouse
models of multiple sclerosis, traumatic brain injury, and Alzheimer's disease
at the Neuroscience 2012 conference held in New Orleans in October 2012.

In January 2012, Rock Creek Pharmaceuticals reported research on the first
clinical trial demonstrating that Anatabloc^® lowers chronic inflammation
measured by CRP levels in the blood. The reported results were obtained in
connection with an in-house study undertaken by Rock Creek that involved a
group of smokers who had been using Anatabloc^® on an extended basis. In
October 2012, Rock Creek reported on an interim look at the CRP results in a
study sponsored by the Roskamp Institute and designed to assess the safety,
tolerability, dosing, and biological effects of anatabine citrate. Currently,
a clinical study of individuals with mild to moderate Alzheimer's disease is
being sponsored by Rock Creek Pharmaceuticals and conducted at the Roskamp

Prior to the introduction of the Company's first dietary supplement, research
scientists at Harvard University's McLean Hospital completed extensive
research, which was funded by Rock Creek Pharmaceuticals, relating to the
safety of anatabine as well as its non-nicotinic effects in connection with
development of the product.

Furthermore, The article's implication or suggestion that Johns
Hopkins has had no involvement in anatabine research is also false. As
previously reported, a preclinical investigator-initiated and independently
funded study from Johns Hopkins examined the effect of anatabine
supplementation on autoimmune thyroiditis in a mouse model and that research
was recently published in an article entitled, "Anatabine Ameliorates
Experimental Autoimmune Thyroiditis" in the Endocrine Society's journal,
Endocrinology. (Endocrinology. 2012 Sep; 153(9):4580-7.) All three of the
published articles referenced in this press release were peer reviewed
anonymously by experts in the field chosen by the editors of the journals.

Star Scientific notes that the author of the article in, Adam
Feuerstein, has published a number of negative articles regarding the Company
and its research on anatabine. The Company believes that investors and
consumers of its Anatabloc® product would be well advised to view any such
articles by this author or publications regarding the Company in
with substantial skepticism, given the misstatements and misinformation that
the author disseminates.

Star Scientific takes its responsibilities to provide and present accurate
information about and to respond to false statements about its products very
seriously. This press release and communications that are being sent to The
Street and its author by Star Scientific's attorneys are examples of that

Certain statements contained in this release constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include, but are not limited to statements identified
by words such as "believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The statements in this
release are based upon the current beliefs and expectations of our company's
management and are subject to significant risks and uncertainties. Actual
results may differ from those set forth in the forward-looking statements.
Numerous factors could cause or contribute to such differences, including, but
not limited to, results of clinical trials and/or other studies, the
challenges inherent in new product development initiatives, including the
continued development and market acceptance of our nutraceutical products, the
effect of any competitive products, our ability to license and protect our
intellectual property, our ability to raise additional capital in the future
that is necessary to maintain our business, changes in government policy
and/or regulation, as well as other risks discussed from time to time in our
filings with the Securities and Exchange Commission, including, without
limitation, our annual report on Form 10-K for the fiscal year ended December
31, 2011. We undertake no duty to update any forward-looking statement or any
information contained in this press release or in other public disclosures at
any time.

About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to
promote maintenance of a healthy metabolism and lifestyle. Over the last
several years, through its wholly owned subsidiary, Rock Creek
Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale,
and marketing of two nutraceutical dietary supplements, and the development of
other nutraceuticals and pharmaceuticals. The company also continues to pursue
the licensing of the technology behind its proprietary StarCured® curing
process and its related products. Rock Creek Pharmaceuticals has scientific
and research offices in Gloucester, MA, and a regulatory office in Washington,
DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, and an
Executive, Scientific & Regulatory Affairs office in Washington, DC.

Talhia T. Tuck
Vice President, Communications and Investor Relations
Star Scientific, Inc.

SOURCE Star Scientific, Inc.

Press spacebar to pause and continue. Press esc to stop.